Prof. Hongsheng Liu | Pharmaco-Oncology | Best Researcher Award

Prof. Hongsheng Liu | Pharmaco-Oncology | Best Researcher Award

Liaoning University | China

Author Profile

Scopus

🌟 Professor Hongsheng Liu: A Pioneer in Microbiology and Bioinformatics

Professor, School of Pharmaceutical Sciences, Liaoning University, China

🔬 Academic and Professional Background

Professor Hongsheng Liu obtained a Master’s degree in Microbiology from China Agricultural University in 1991 and later pursued a Ph.D. in Microbiology and Bioinformatics at Gifu University School of Medicine, Japan, in 2004. Over the years, he has expanded his expertise by serving as a visiting scholar at prestigious institutions such as Wuhan University, the University of Hong Kong, Harvard Medical School, and Hebrew University of Jerusalem. His career reflects a deep commitment to advancing the fields of microbiology, bioinformatics, and pharmaceutical sciences.

💡 Research and Innovations

Professor Liu has completed an impressive 74 research projects and authored over 100 journal articles (SCI, Scopus, etc.), accumulating a citation index of 2721. His work spans diverse areas, including the discovery of the novel microorganism Paenibacillus liaoningensis sp. nov. and the investigation of influenza virus interactions. His contributions to computational biology include the development of several predictive algorithms and online platforms like CarcinoPred-EL and LiverToxPred-EL. Additionally, Professor Liu holds 37 patents, has published 4 books, and has led 7 industry consultancy projects.

📚 Published Works and Collaborations

Professor Liu’s collaborative research includes partnerships with renowned institutions such as the University of Toledo, Harvard Medical School, and Eberhard Karl University of Tübingen. He has also served as a guest editor for Frontiers in Microbiology (2017-2018). His dedication to both basic and applied research continues to push the boundaries of pharmaceutical sciences.

👥 Professional Memberships

He is an active member of the Chinese Society for Microbiology (CSM) and the Chinese Chemical Society (CCS).

🌍 Areas of Research

Professor Liu specializes in computer-aided drug design and the simulation of biomacromolecule interactions, with a focus on studying lncRNAs and disease relationships, and designing stable recombinant proteins using engineered bacteria.

🔔 Conclusion

Professor Hongsheng Liu stands as a distinguished leader in microbiology and bioinformatics, contributing significantly to drug design, biomolecular simulation, and microbial discovery. His broad academic collaborations, cutting-edge innovations, and vast research output underscore his influence in the scientific community. Through his extensive work on predictive algorithms, microbial databases, and recombinant protein design, he has made impactful advancements in pharmaceutical sciences. With over 100 journal publications, 37 patents, and numerous prestigious collaborations, Professor Liu’s dedication to advancing scientific knowledge and improving human health is truly commendable.

📊🔬NOTABLE PUBLICATION:

    • Article Title: Ensemble multiclassification model for aquatic toxicity of organic compounds
      Authors: Li, X., Liu, G., Wang, Z., Liu, H., Ai, H.
      Journal: Aquatic Toxicology
      Year: 2023

     

    • Article Title: Construction of an oxidative stress-related lncRNAs signature to predict prognosis and the immune response in gastric cancer
      Authors: Zhang, H., Feng, H., Yu, T., Ma, L., Liu, H.
      Journal: Scientific Reports
      Year: 2023

     

    • Article Title: CBIL-VHPLI: a model for predicting viral-host protein-lncRNA interactions based on machine learning and transfer learning
      Authors: Zhang, M., Zhang, L., Liu, T., Zhao, J., Liu, H.
      Journal: Scientific Reports
      Year: 2024

     

    • Article Title: Construction of highly active and stable recombinant nattokinase by engineered bacteria and computational design
      Authors: Wang, L., Meng, J., Yu, X., Zhang, L., Liu, H.
      Journal: Archives of Biochemistry and Biophysics
      Year: 2024

     

    • Article Title: Effects of dietary supplementation of gallic tannic acid on growth, intestinal digestive enzymes activity, innate immunity, morphology, and microbial composition of Cyprinus carpio
      Authors: Feng, H., Zhao, S., Ma, X., Liu, Z., Liu, H.
      Journal: Aquaculture International
      Year: 2024

Dr. Yuta Yamanaka | Lung Cancer | Best Researcher Award

Dr. Yuta Yamanaka | Lung Cancer | Best Researcher Award

Kansai Medical University Hospital | Japan

AUTHOR PROFILE

Scopus

ORCID Id

🧑‍🎓 EARLY ACADEMIC PURSUITS 📚

Dr. Yuta Yamanaka embarked on his medical journey with a deep interest in oncology, focusing particularly on thoracic diseases. He completed his Medical Degree from a prestigious Japanese university, demonstrating a clear passion for cancer research, specifically targeting lung cancer. His early education laid a robust foundation in both clinical medicine and research methodologies, setting the stage for his future breakthroughs in thoracic oncology.

🩺 PROFESSIONAL ENDEAVORS 🏥

Dr. Yamanaka is a renowned thoracic oncologist at Kansai Medical University Hospital, one of Japan’s leading institutions for cancer treatment. His medical career is marked by his dedication to patient care, coupled with his pursuit of cutting-edge research in lung cancer. As a departmental leader, Dr. Yamanaka has played a crucial role in developing new protocols for the management and treatment of thoracic malignancies. His efforts have enhanced both the clinical approach and patient outcomes at the hospital.

🔬 CONTRIBUTIONS AND RESEARCH FOCUS ON LUNG CANCER🔍

Dr. Yamanaka’s primary research focus is on lung cancer, particularly in the early detection, diagnosis, and treatment of this aggressive disease. He is actively involved in clinical trials exploring novel therapeutic strategies, including targeted therapies and immunotherapy. His research has contributed to the development of new approaches to personalize treatment for lung cancer patients, making strides in precision oncology.

Additionally, Dr. Yamanaka has worked on improving the understanding of tumor biology in thoracic cancers and has published extensively on the molecular mechanisms underlying lung cancer progression.

🌍 IMPACT AND INFLUENCE 💡

Dr. Yamanaka’s work has not only impacted the lives of his patients but has also influenced the broader field of thoracic oncology. His clinical trials have pushed the boundaries of what is possible in lung cancer treatment, helping to establish new standards of care. Moreover, his contributions to the understanding of lung cancer at a molecular level have provided other researchers with critical insights, fostering global collaborations.

🏆 ACADEMIC CITES AND RECOGNITION 📜

Dr. Yamanaka has been widely cited in prestigious oncology journals for his pioneering work on lung cancer. His research has garnered international recognition, with citations numbering in the thousands, reflecting his influence in both clinical and academic spheres. He frequently presents his findings at global oncology conferences and serves as a reviewer for leading medical journals.

🔮 LEGACY AND FUTURE CONTRIBUTIONS 🌟

Looking forward, Dr. Yamanaka is poised to continue his groundbreaking work in thoracic oncology. His future research is expected to delve deeper into early-stage lung cancer detection, with the goal of significantly improving survival rates. He remains dedicated to exploring new frontiers in personalized medicine and further enhancing treatment outcomes for lung cancer patients through novel therapeutics and multimodal therapies.

Dr. Yamanaka’s legacy will undoubtedly be marked by his relentless pursuit of innovation and excellence in the treatment of thoracic cancers, securing his place as a leading figure in the global fight against lung cancer.

Dr. Yuta Yamanaka’s work in the field of lung cancer research and clinical care makes him a vital contributor to both Japanese and international oncology communities. His dedication continues to shape the future of thoracic oncology, with the promise of many more contributions to come.

✨ CONCLUSION 🎯

Dr. Yuta Yamanaka stands as a trailblazer in the field of thoracic oncology, particularly in his groundbreaking research and clinical advancements in lung cancer. His early academic pursuits laid a solid foundation for an impressive career marked by innovation, dedication, and compassion. As a respected leader at Kansai Medical University Hospital, his efforts in advancing targeted therapies, improving patient outcomes, and deepening the global understanding of lung cancer have left an indelible mark on both the medical community and the lives of countless patients.

 

📊🔬NOTABLE PUBLICATION:

 

    • Clinical significance of factor XIII activity and monocyte-derived microparticles in cancer patients
      • Authors: Sawai, Y., Yamanaka, Y., Nomura, S.
      • Journal: Vascular Health and Risk Management
      • Year: 2020

     

    • Age-Stratified Analysis of First-Line Chemoimmunotherapy for Extensive-Stage Small Cell Lung Cancer: Real-World Evidence from a Multicenter Retrospective Study
      • Authors: Takeda, T., Yamada, T., Kunimatsu, Y., Kurata, T., Takayama, K.
      • Journal: Cancers
      • Year: 2023

     

    • Multicenter Pharmacokinetic and Pharmacodynamic Study of Pembrolizumab for Non-small-Cell Lung Cancer in Patients Aged 75 Years and Older
      • Authors: Yagishita, S., Yamanaka, Y., Kurata, T., Mizugaki, H., Hamada, A.
      • Journal: Clinical Pharmacology and Therapeutics
      • Year: 2024

     

    • Paraneoplastic Neurological Syndrome-associated Antibody-positive Small-cell Lung Cancer Diagnosed with Preceding Neurological Symptoms: a Case Series 
      • Authors: Okazaki, Y., Yoshioka, H., Kamisako, K., Yamanaka, Y., Kurata, T.
      • Journal: Japanese Journal of Lung Cancer
      • Year: 2024

     

    • Investigation of a practical assessment index to capture the clinical presentation of cachexia in patients with lung cancer
      • Authors: Katsushima, U., Hase, K., Fukushima, T., Imai, Y., Kurata, T.
      • Journal: Japanese Journal of Clinical Oncology
      • Year: 2024

Prof Dr.Sheeren Mohammed Khaled – Cancer Science – Best Researcher Award

Prof Dr.Sheeren Mohammed Khaled - Cancer Science - Best Researcher Award

King Abdullah Medical City - Saudi Arabia

AUTHOR PROFILE

Scopus

Orcid

EARLY ACADEMIC PURSUITS:

Dr. Sheeren Mohammed Khaled began her academic journey with a Bachelor of Medicine and Surgery (M.B., B.Ch.) from Benha University, Faculty of Medicine, graduating with excellence in December 2005. Following this, she pursued her Master's degree in Cardiology at Benha University, graduating with a very good grade in September 2010. Dr. Khaled continued her academic endeavors, earning her MD degree in Cardiology from Benha University in May 2014.

PROFESSIONAL ENDEAVORS:

Dr. Khaled's professional journey reflects a rich and diverse experience in the field of Cardiology: Consultant Cardiology at King Abdullah Medical City (KAMC), Associate Professor of Cardiology at Benha University, Lecturer of Cardiology at Benha University Hospital, Associate Consultant Cardiology at KAMC, Cardiology Specialist at Alzahra Hospital (Saudi Arabia), Assistant Lecturer at Benha University Hospital.

IMPACT AND INFLUENCE ON CANCER SCIENCE

Dr. Sheeren Mohammed Khaled has made significant contributions to the field of cancer science through her roles as a clinician, educator, and researcher. Her commitment to teaching, clinical excellence, and research activities has had a positive impact on both students and colleagues.

ACADEMIC CITATIONS:

Dr. Khaled's academic citations are reflective of her contributions to research studies, the supervision of theses, and active involvement in various scientific committees.

LEGACY AND FUTURE CONTRIBUTIONS:

Dr. Sheeren Mohammed Khaled's legacy lies in her dedication to advancing cardiology education, patient care, and research. Her future contributions are anticipated to further enrich the field through continued excellence in teaching, clinical practice, and impactful research initiatives.

NOTABLE PUBLICATIONS

Myocardial recovery after percutaneous coronary intervention in coronary artery disease patients with impaired systolic function- predictive utility of global longitudinal strain.2022

Severe Left Ventricular Dysfunction Earlier after Acute Myocardial Infarction Treated with Primary Percutaneous Coronary Intervention: Predictors and In-Hospital Outcome– A Middle Eastern Tertiary Center Experience.2023

Cardiogenic Shock Among Patients with Acute ST-Segment Elevation Myocardial Infarction in a Middle Eastern Country: A Single-Center Experience.2023